New Product Planning
Take New Biopharmaceuticals from Plan to Patient
Our industry-experienced consultants have a deep understanding of new product planning – the steps, the priorities, the hurdles, and the management of assets well beyond launch.
Your biopharma therapies have the opportunity to change lives for the better.
We have helped hundreds of biotech and pharmaceutical companies plan, develop, and commercialize products that change lives.
Our industry-experienced consultants have a deep understanding of new product planning – the steps, the priorities, the hurdles, and the management of assets well beyond launch.
Elements of Successful New Product Planning
Building Differentiation Into New Biopharmaceuticals
Early-stage assessments provide reliable data to inform the target product profile (TPP) of your new product.
We bring clinical and commercial teams into alignment to develop medical innovations with viable commercial potential.
From concept to commercialization and from launch through lifecycle, we develop meticulous plans for known challenges. When the unknown rears up to throw a plan off course, our deeply experienced biopharma consultants have the flexibility to adapt quickly.
Biopharmaceuticals Platform Expertise
Our wide-ranging experience allows us to be platform agnostic. Platforms we have worked in most frequently include:
- Small Molecule Therapy
- Gene Therapy
- Cell Therapy
- Biologics: Antibodies, Proteins, etc.
- Radiopharmaceuticals/Imaging
- Contrast Media
Case Study
New Pharma Product Forecasts Bring Partners and Investors on Board
Clinical-stage pharmaceutical company developing the next generation of oncolytic viral immunotherapies for solid tumors.
The client was preparing to open discussions with potential partners and investors.
To elevate their appeal, they asked for US market landscapes and revenue forecasts for six types of tumors.
We examined the product profile’s possible impact on the current market landscape and explored how the treatment landscape will likely evolve in the coming years.
For each of the six tumor types, The NemetzGroup developed a US market landscape summary and a 15-year revenue forecast model for the US, EU, and ROW.
We worked closely with the program team, so our forecast approach remained aligned with the client’s needs throughout the project.
Our client had renewed confidence in their valuation and used the forecast models to negotiate a term sheet with a partner and to open discussions with early investors in advance of a public offering.
Discover More About New Product Planning
Expand your knowledge with our curated collection of additional resources.
